PropThink

About the Author PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market coverage and actionable research to PropThink Premium and Premium Plus subscribers.

Biogen Idec Inc Meets Expectations With Early Alzheimer’s Drug


Even after adding $30 billion in market value over the last four months, shares of Biogen Idec Inc (NASDAQ:BIIB) moved higher on Friday morning with the release of details from a phase 1 trial of the experimental Alzheimer’s treatment, aducanumab (BIIB037).

Biogen first teased the results late last year, saying that the amyloid-clearing antibody produced statistically significant improvements in cognitive function and amyloid clearance in patients with the degenerative disease. On Friday, investors got a first look at the data during a presentation in Nice, France, and the stock was up 10% (about $10 billion in market value) in pre-market trading.

Aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain, as well as a statistically significant positive effect on clinical decline based on two exploratory endpoints: the Mini Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scales.

At week 54, aducanumab treatment resulted in a statistically significant reduction of amyloid plaque in the 3 mg/kg (p<0.001) and 10 mg/kg (p<0.001)] dose arms. The reduction of amyloid plaque in the 1 mg/kg arm was not significant. 54-week data from a newer 6 mg/kg arm, added partway through the study, will be available later.

On the MMSE, patients receiving placebo worsened by an average of 3.14 at 54 weeks. In the 1mg/kg arm, the change was 2.21; 0.75 in the 3 mg/kg arm; and 0.58 in the 10 mg/kg arm. Compared to placebo, this apparent slowing in cognitive decline from the 3 mg/kg and 10 mg/kg doses was statistically significant (p <0.05).

On the CDR-SB, patients in the placebo group worsened by an average of 2.04 at 54 weeks. The worsening was 1.70 in the 1 mg/kg arm, 1.33 in the 3 mg/kg arm and 0.59 in the 10 mg/kg arm. Just the 10 mg/kg’s slowing of clinical decline was statistically significant (p <0.05).

The important takeaway: the reductions appear to be dose-dependent, meaning the drug is “active”.

This was an interim analysis of the PRIME study, testing BIIB037 in 166 early Alzheimer’s patients. The placebo arm had 40 patients, the 1 mg/kg had 31, 3 mg/kg had 33, 10 mg/kg had 32. A 6 mg/kg (n=30) dose arm was added further into the study in order to identify an ideal dose, which may be split between 10 and 3 mg/kg.

The most worrying safety event was an increased incidence of ARIA-E (edema, or brain swelling) in patients receiving the highest dose, and especially in patients with a variant of the APOE4 gene. In ApoE4 carriers, the incidence of ARIA-E was 5% in the 1 mg/kg and 3 mg/kg arms, 43% in the 6 mg/kg arm, and a whopping 55% in the 10 mg/kg arm. This is why BIIB began testing a 6mg dose.

Bottom line: While investors are celebrating, it’s important to keep in mind that these are small sample sizes. This is the most encouraging data from the amyloid-clearing class of drugs over the years, but it was similar optimism that precluded major phase 3 blowups for products like Elan’s (ELN) Bapineuzumab and Eli Lilly’s (LLY), solanezumab.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts